NCT05116930View on ClinicalTrials.gov

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Post-Dural Puncture Headache
Interventions
DRUG

Neostigmine

IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses

DRUG

Glycopyrrolate

IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05116930 - Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture | Biotech Hunter | Biotech Hunter